Shenzhen Kaili Biomedical Technology Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The Company held the 14th meeting of the 4th Board of Directors on March 17, 2026, to review and approve the proposal regarding the share buyback plan. The Company agreed to use its own or raised funds (including funds from special loans for share buyback) to repurchase shares through centralized bidding, with all repurchased shares intended for cancellation and reduction of registered capital. For specific details, please refer to the announcement on the share buyback plan disclosed on March 18, 2026, on the designated information disclosure website of the China Securities Regulatory Commission (Announcement No. 2026-002).